Blueprint Medicines to Present Preclinical Data at 2015 ASH Annual Meeting Demonstrating Anti-tumor Activity of BLU-285 in a Model of Acute Myeloid Leukemia
KIT Exon 17 mutations have been identified as drivers in multiple diseases, and the presence of these mutations greatly reduces the effective treatment options available to patients. BLU-285 is a potent and highly selective inhibitor of KIT Exon 17 and PDGFRα D842V mutants, which are drivers of disease in patients with gastrointestinal stromal tumors (GIST) and systemic mastocytosis (SM).
In AML, a subset of patients with the t(8;21) translocation and an additional KIT Exon 17 mutation are at increased risk of recurrence compared to those without it, creating a strong need for new therapies to address their form of the disease.
In preclinical results to be presented by
"We are encouraged by these preclinical results, which further strengthen our belief that BLU-285 may play an important role in multiple hematologic and solid tumor malignancies," said
ASH presentation details:
Date & Time: |
Monday Dec. 7, 2015; 11:15 AM EST |
Presentation Title: |
BLU-285, a Potent and Selective Inhibitor for Hematologic Malignancies with KIT Exon 17 Mutations |
Presenter: |
Erica K. Evans, PhD, Director, Biology, Blueprint Medicines |
Abstract Number: |
568 |
Location: |
Orange County Convention Center, W 109 |
9800 International Drive, Orlando, FL 32819 |
About the Phase 1 Clinical Trials for BLU-285
The Phase 1 clinical trial for BLU-285 for the treatment of unresectable, treatment-resistant GIST will evaluate the safety and tolerability of BLU-285 in multiple ascending doses with the goal of establishing a maximum tolerated dose (MTD) or a recommended dose if the MTD is not achieved.
The planned Phase 1 clinical trial for BLU-285 for the treatment of advanced SM will evaluate the safety and tolerability of BLU-285 in multiple ascending doses with the goal of establishing an MTD or a recommended dose if the MTD is not achieved.
About
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding the potential for BLU-285 to provide clinical benefit to patients and
Logo - http://photos.prnewswire.com/prnh/20150605/221118LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/blueprint-medicines-to-present-preclinical-data-at-2015-ash-annual-meeting-demonstrating-anti-tumor-activity-of-blu-285-in-a-model-of-acute-myeloid-leukemia-300177503.html
SOURCE
Investor Relations: Hannah Deresiewicz, Stern Investor Relations, Inc., 212-362-1200, hannahd@sternir.com, Media Relations: Dan Quinn, Ten Bridge Communications, Inc., 781-475-7974, dan@tenbridgecommunications.com